Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $129.43 Consensus Price Target from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have received a consensus rating of "Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $129.43.

Several research firms have recently commented on LNTH. B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. JMP Securities reiterated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th.

Insider Buying and Selling

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 over the last three months. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in Lantheus in the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the fourth quarter valued at $27,000. Summit Securities Group LLC acquired a new position in Lantheus during the fourth quarter valued at $37,000. UMB Bank n.a. raised its position in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust boosted its position in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after acquiring an additional 280 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

LNTH traded up $0.17 on Thursday, reaching $102.87. The company's stock had a trading volume of 116,269 shares, compared to its average volume of 859,949. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of 17.14 and a beta of 0.20. The business's 50 day moving average is $97.80 and its 200 day moving average is $95.08. Lantheus has a 1 year low of $65.89 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, research analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.